Biotech Values

[Preciouslife1]

Tiny NWBT has news out and is moving on decent volume this am:
Northwest Biotherapeutics, Inc.

(NWBT) Current Price (0.19) www.SmallCapStockAlert.com BOTHELL, Wash., April 17 -- Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBT - News), today announced that it has filed for Authorization for Use of its DCVax -Brain therapeutic vaccine in Switzerland to treat patients with malignant brain cancers, including Glioblastoma multiforme (GBM), the most aggressive and lethal form of brain cancer. If approved, Northwest Biotherapeutics will be authorized to commercialize, market and import/export DCVax -Brain for the treatment of patients at selected centers in Switzerland. The application, submitted to the Swiss Institute of Public Health or Bundesamt fur Gesundheit (BAG), will be reviewed by the BAG and Swissmedic. Northwest Biotherapeutics expects to receive a decision from the BAG during Q3 of this year. Northwest Biotherapeutics, Inc., a development stage biotechnology company, engages in the discovery, development, and commercialization of immunotherapy products to treat cancer. It has two platform technologies, dendritic cell-based cancer vaccines and monoclonal antibodies for cancer therapeutics. The company's primary products include DCVax-Prostate, a personalized dendritic cell vaccine for treatment of hormone independent nonmetastatic prostate cancer, which is entering Phase III clinical trial; DCVax-Brain, a personalized dendritic cell vaccine, which is entering Phase II clinical trials, for treatment of Glioblastoma multiforme. Northwest Biotherapeutics also develops monoclonal antibodies to CXCR4, what are in late preclinical development stages for the treatment of cancers, including breast cancer, glioblastoma, colon cancer, and melanoma. In addition, it develops DCVax-Lung, a Phase I clinical trial product for the treatment of nonsmall cell lung cancer; and DCVax-Direct, which is under preclinical stages for the treatment of head and neck cancer, nonsmall cell lung, and brain cancers. The company was founded in 1996 and is headquartered in Bothell, Washington.

This is a tiny biotech company with very good technology and
probably has less cash then Dew has in his Christmas account, but has promising tech and is a very low priced play in the oncological field especially GBM, head and neck cancers FWIW.